Coherus Oncology Inc’s recently made public that its Director Wahlstrom Mats unloaded Company’s shares for reported $73881.0 on May 23 ’25. In the deal valued at $0.74 per share,99,988 shares were sold. As a result of this transaction, Wahlstrom Mats now holds 0 shares worth roughly $0.0.
UBS downgraded its Coherus Oncology Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Oncology Inc [NASDAQ:CHRS] saw its stock fall -7.88% to $0.75. Over the last five days, the stock has gained 0.42%. Coherus Oncology Inc shares have fallen nearly -46.32% since the year began. Nevertheless, the stocks have fallen -45.93% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 06/23/25.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 0.7235, which if violated will result in even more drops to 0.7007. On the upside, there is a resistance level at 0.7785. A further resistance level may holdings at 0.8107.
How much short interest is there in Coherus Oncology Inc?
A steep rise in short interest was recorded in Coherus Oncology Inc stocks on 2025-06-13, dropping by -1.17 million shares to a total of 31.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 33.12 million shares. There was a decline of -3.68%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
